PYXS - Pyxis Oncology, Inc. Stock Price, Fair Value and News

$3.57+0.07 (+2.00%)

Delayed as of 23 Oct 2024, 03:00 pm ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

PYXS Price Action

Last 7 days

8.0%

Last 30 days

-5.1%

Last 90 days

-7.2%

Trailing 12 Months

118.8%

PYXS RSI Chart

PYXS Valuation

Market Cap

206.3M

Price/Earnings (Trailing)

-3.48

Price/Sales (Trailing)

9.61

Price/Free Cashflow

-3.63

PYXS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PYXS Fundamentals

PYXS Revenue

Revenue (TTM)

21.5M

Rev. Growth (Yr)

22.16%

Rev. Growth (Qtr)

-87.47%

PYXS Earnings

Earnings (TTM)

-59.2M

Earnings Growth (Yr)

-8.8%

Earnings Growth (Qtr)

-431.36%

PYXS Profitability

Return on Equity

-34.87%

Return on Assets

-28.41%

Free Cashflow Yield

-27.56%

PYXS Investor Care

Shares Dilution (1Y)

49.12%

Diluted EPS (TTM)

-1.25

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	21.1M	21.5M	0	0
2023	4.3M	5.9M	6.9M	6.6M
2022	1.0M	0	1.9M	2.8M
2021	0	0	0	181.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Pyxis Oncology, Inc.

Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Lara S. Sullivan M.D., MBA
WEBSITE	https://pyxisoncology.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	72

Pyxis Oncology, Inc. Frequently Asked Questions

What is the ticker symbol for Pyxis Oncology, Inc.? What does PYXS stand for in stocks?

PYXS is the stock ticker symbol of Pyxis Oncology, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pyxis Oncology, Inc. (PYXS)?

As of Tue Oct 22 2024, market cap of Pyxis Oncology, Inc. is 206.3 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PYXS stock?

You can check PYXS's fair value in chart for subscribers.

Is Pyxis Oncology, Inc. a good stock to buy?

The fair value guage provides a quick view whether PYXS is over valued or under valued. Whether Pyxis Oncology, Inc. is cheap or expensive depends on the assumptions which impact Pyxis Oncology, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PYXS.

What is Pyxis Oncology, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Oct 22 2024, PYXS's PE ratio (Price to Earnings) is -3.48 and Price to Sales (PS) ratio is 9.61. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PYXS PE ratio will change depending on the future growth rate expectations of investors.